Publications
Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011. PMID: 21387258
Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell metabolism. 2011. PMID: 21356520
Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Current treatment options in oncology. 2011. PMID: 21274667
Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Current opinion in hematology. 2011. PMID: 21252655
O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, National Comprehensive Cancer Network. Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN. 2011. PMID: 21393440
Peng J, Chen W, Venook AP, Sheng W, Xu Y, Guan Z, Cai G, Cai S. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clinical colorectal cancer. 2011. PMID: 21609934
McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PMID: 21350003
Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. The oncologist. 2011. PMID: 21339259
Digambaranath JL, Campbell TV, Chung A, McPhail MJ, Stevenson KE, Zohdy MA, Finke JM. An accurate model of polyglutamine. Proteins. 2011. PMID: 21337625
Parsons ML, Cornett PA. Sustaining the pivotal organizational outcome: magnet recognition. Journal of nursing management. 2011. PMID: 21375632
Slorach EM, Chou J, Werb Z. Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes & development. 2011. PMID: 21317240
Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. Journal of neuro-oncology. 2011. PMID: 21311950
Turner NC, Ashworth A. Biomarkers of PARP inhibitor sensitivity. Breast cancer research and treatment. 2011. PMID: 21301956
Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future oncology (London, England). 2011. PMID: 21345145
Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. PMID: 21263089
Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, Coupland B, Broderick P, Schoemaker M, Jones M, Williamson J, Chilcott-Burns S, Tomczyk K, Simpson G, Jacobs KB, Chanock SJ, Hunter DJ, Tomlinson IP, Swerdlow A, Ashworth A, Ross G, dos Santos Silva I, Lathrop M, Houlston RS, Peto J. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. Journal of the National Cancer Institute. 2011. PMID: 21263130
Komanduri KV, Champlin RE. Can Treg therapy prevent GVHD? Blood. 2011. PMID: 21252098
Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Current opinion in genetics & development. 2011. PMID: 21255997
Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. PMID: 21245436
Rosenbluth JM, Mays DJ, Jiang A, Shyr Y, Pietenpol JA. Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 2011. PMID: 21245298